Session » (0543–0581) SLE – Diagnosis, Manifestations, & Outcomes Poster I

Date: Sunday, November 12, 2023

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2023

9:00AM-11:00AM: Abstract Number: 0571

A Polygenic Risk Score for Systemic Lupus Erythematosus (SLE) Discriminates Between Patients with Lupus and Individuals Without Lupus and a Positive Antinuclear Antibody Test

9:00AM-11:00AM: Abstract Number: 0554

A Refined Disease Activity Immune Index Informed by Select Immune Mediators That Characterizes Clinical Disease Activity in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 0547

A Spatially-resolved Single Cell Resolution Atlas of Pediatric Lupus Nephritis Uncovers Complex Interactions Between Stromal and Infiltrating Immune Cells

9:00AM-11:00AM: Abstract Number: 0577

Analysis of Intracytoplasmic Toll – Like Receptors (TLRs) and MyD88 Expression in B Cell Subsets in Patients with Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 0544

Autoantibodies to dsDNA and Associated Proteins: Association with Proteinuria and Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 0570

BLyS Levels Are Elevated in Systemic Lupus Erythematosus Patients with Neuropsychiatric Manifestations

9:00AM-11:00AM: Abstract Number: 0566

Characterization of Disease Activity Using a Novel Physiologic Biomarker in Pediatric SLE

9:00AM-11:00AM: Abstract Number: 0556

Classical Complement Activation in Lupus Nephritis Correlates with Disease Biomarkers: Results from Two Observational Studies

9:00AM-11:00AM: Abstract Number: 0548

Clinical and Interferon Biomarkers to Exclude Imminent Autoimmune Disease in ANA Positive Individuals

9:00AM-11:00AM: Abstract Number: 0568

Comparison of Plasma Protein Profiles and Endothelial Function in Patients with Pediatric-Onset Systemic Lupus Erythematosus and Healthy Controls

9:00AM-11:00AM: Abstract Number: 0559

Development of Charlson Comorbidity Index (CCI) Comorbidities and CCI Score in Danish Nationwide Cohort of 3,178 Patients with Newly Diagnosed Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 0549

Development of Customized Digital Cognitive Assessment Battery: A Pilot Use Case in SLE Patients

9:00AM-11:00AM: Abstract Number: 0558

Elevated Serum Levels of S100A8/A9 Discriminate Systemic Lupus Erythematosus Patients with Cognitive Impairment from Patients Without Impairment

9:00AM-11:00AM: Abstract Number: 0576

Enhancing Systemic Lupus Erythematosus Diagnosis: Comparative Performance Characteristics of TC4d and Anti-T-Cell Antibodies with Conventional Biomarkers

9:00AM-11:00AM: Abstract Number: 0555

Evaluation and Management of the “False Positive” ANA and Undifferentiated Connective Tissue Disease Amongst Rheumatologists

9:00AM-11:00AM: Abstract Number: 0561

Frequency of Anti-Ro Antibodies in Systemic Lupus Erythematosus Patients: Insights from Multicenter and National Registry

9:00AM-11:00AM: Abstract Number: 0560

Genetic Determinants of Lupus Nephritis and Kidney Function in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 0550

Harnessing Machine Learning to Predict Neuropsychiatric Events in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 0562

HDL-Cholesterol Efflux and the Complement System Are Linked in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 0565

Insulin Resistance and the Complement System Are Linked in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 0557

Longitudinal Evaluation of Cell-bound Complement Activation Products in Patients with SLE

9:00AM-11:00AM: Abstract Number: 0546

Markers of Oxidative Stress in Systemic Lupus Erythematosus Patients with Nephritis

9:00AM-11:00AM: Abstract Number: 0551

Monogenic Lupus: Clinical Phenotypes and Genetic Mutations in a Cohort of Pediatric Patients

9:00AM-11:00AM: Abstract Number: 0567

N-Terminal Pro-Brain Natriuretic Peptide Correlates Strongly with Cardiovascular Damage in Systemic Lupus Erythematous (SLE): A Cross-sectional Study

9:00AM-11:00AM: Abstract Number: 0581

Performance Characteristics of a Novel, Fully Automated Multiplexed Immunoassay Microarray Prototype for the Serological Detection of Eleven IgG Autoantibodies Commonly Found in Connective Tissue Diseases

9:00AM-11:00AM: Abstract Number: 0580

Performance of Conventional Cardiovascular Risk Scores in Identifying Subclinical Atherosclerosis in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 0573

Presence of Mediterranean Fever Gene Variants Provides Protection from the Development of Lupus Nephritis in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 0578

Prospective Observational Study of Microvascular C5b-9 Deposition in Non-lesional Skin in Systemic Lupus Erythematosus Patients and Its Correlation with Active Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 0545

Referral Pattern and Factors Associated with Time to Diagnosis for Lupus in India- multicentric Data from the SLE Special Interest Group (SIG) of the Indian Rheumatology Association (IRA)

9:00AM-11:00AM: Abstract Number: 0564

Risk Factors for Immune Thrombocytopenia in Systemic Lupus Erythematosus and Generation of a Predictive Model to Assess Its Risk of Development

9:00AM-11:00AM: Abstract Number: 0543

Sensitivity of the 2019 European Alliance of Associations for Rheumatology /American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus in a Population-based Cohort; A Study Set in Norway 2000-2015

9:00AM-11:00AM: Abstract Number: 0553

Serum Isolevuglandin IgG Antibody Concentrations Are Increased in Patients with Systemic Lupus Erythematosus versus Control Subjects and Associated with Lower 24-hour Blood Pressure

9:00AM-11:00AM: Abstract Number: 0569

Serum S100A8 and S100A9 Are Useful Biomarker Indicated IFN Associated Organ Involvements in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 0572

Serum/ Urine Levels and Expression of CD163 in Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 0579

Sub-types of Ischemic Stroke in Systemic Lupus Erythematosus,-associations with STAT4 and HLA-DRB1 Risk Genotypes

9:00AM-11:00AM: Abstract Number: 0552

The Impact of Antiphospholipid Antibodies on Future Atherosclerotic Cardiovascular Disease Risk in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 0575

The Real-World Utility of a Lupus Activity Monitoring Panel in the United States Community Rheumatologist Practice

9:00AM-11:00AM: Abstract Number: 0574

Type I IFN-associated Regulation of Immune Checkpoint Genes in Patients with SLE

9:00AM-11:00AM: Abstract Number: 0563

Urinary Neutrophil Gelatinase-associated Lipocalin (NGAL) as a Mediator of the Association Between Particulate Matter Exposure and Disease Activity in Systemic Lupus Erythematosus

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].